Sanofi and Regeneron Pharmaceuticals have successfully completed a phase 3 trial of Dupixent, PRIME2. The study investigated the treatment of uncontrolled prurigo, a type 2 skin condition that causes severe itching and skin lesions. At week 24, a significant reduction in itching was experienced by 58% of patients who received the drug, versus 20% among those who received the placebo. The results of the additional PRIME study are expected in the 1st half of next year. Also in 2022 the partners expect to apply for approval of a new prescription of the drug.